1 Investigating the contribution of circulating inflammatory cytokines on

2 the link between obesity and COVID-19

- 3 Zahra J. Khamis¹, Emmanouil Karteris¹, Amani Alhajeri², Steven G. Smith¹, Alexandra
- 4 Blakemore^{1,3,4}, Fotios Drenos^{1*}
- 5 1 Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel
- 6 University London, London, UK
- 7 2 Government Hospitals, The Genetics Center, Manama, Kingdom of Bahrain
- 8 3 Department of Metabolism, Digestion and Reproduction, Imperial College London,
- 9 London, UK
- 10 4 College of Medicine, Nursing, and Health Science, University of Galway, Galway, Republic
- 11 of Ireland
- 12 * Correspondence: Dr Fotios Drenos
- 13 Department of Life Sciences, College of Health and Life Sciences, Brunel University
- 14 London, Kingston Lane, Uxbridge, Middlesex, UB8 3PH, United Kingdom. +44 (0)1895
- 15 266951- fotios.Drenos@brunel.ac.uk

16 Abstract

Background: Coronavirus disease 2019 (COVID-19), is more severe in individuals with obesity.
Furthermore, a cytokine storm was observed in many critically ill patients with COVID-19. Since
adipose tissue secretes cytokines, we investigated whether cytokines mediate the effect of obesity
on COVID-19 severity.

Methods: Using two-sample Mendelian randomization analyses we assessed the causal effect of body mass index (BMI) on COVID-19 severity. We then evaluated the BMI effect on 41 inflammatory cytokines, as well as on JAK-2, lymphocyte percentage and leptin. We also tested the relationship between these immunological factors and COVID-19 severity. The estimates obtained were used in a mediation analysis to understand the immunological factors linking BMI to COVID-19 severity.

Results: Higher BMI increased the risk of COVID-19 severity. BMI was also causally associated with 5 of the 41 inflammatory cytokines, HGF, TRAIL, IL 13, IL6, and IL 7. We identified TNFa and IL-8 as the only two inflammatory cytokines associated with COVID-19 severity. Leptinrelated genetic variation was associated with COVID-19 severity, but JAK-2 and lymphocyte percentage were not. We found no statistical evidence of mediation of immunological factors tested on the relationship between BMI and COVID-19 severity, although our estimate was 52.8%.

33 **Conclusions:** We replicated the previously reported association between BMI and COVID-19 34 severity. We identified the inflammatory cytokines elevated due to higher BMI. Other 35 inflammatory cytokines showed evidence for increasing COVID-19 severity. However, we were 36 unable to find statistical evidence of baseline levels of circulating cytokines, or additional factors 37 involved in a cytokine storm i.e. JAK-2, lymphocyte percentage, and leptin, mediating the link

38	between BMI and severe COVID-19. Although targeting specific cytokines will be of benefit in
39	the general population, further work on cytokine levels during early phases of COVID-19 infection
40	is needed to provide new approaches to decrease the risk of severe COVID-19 with higher BMI.
41	
42	Keywords: COVID-19: SARS-CoV2: inflammatory cytokines: mediation analysis. Two-sample

- 43 Mendelian randomization (2SMR), Multivariable Mendelian randomization (MVMR), Janus
- 44 kinase 2 (JAK2), leptin, lymphocytes percentage.

45 1 Background

46 Obesity, the excessive accumulation of fat, is considered to be one of the major risk factors for
47 developing severe COVID-19 (1). Several studies indicate that, as body mass index (BMI)
48 increases, so does the risk of mechanical ventilation and ICU admission (2)

Adipose tissue (AT), where body fat is stored, is an active immune organ that regulates hormonal,
metabolic, and immune processes. AT plays an important role in the development of systemic and

51 local low-grade inflammation that is recognized by local infiltration of immune cells, and by

52 elevated circulating proinflammatory factors (3).

53 According to our current understanding, following infection with SARS-CoV2, resident macrophages are activated in adipose tissue. M1-polarized macrophage recruitment promotes the 54 production of local and systematic pro-inflammatory cytokines (IL 8, IL 6, TNF α) resulting in a 55 type-1 immune response (Th1) (4). Individuals with obesity develop a chronic immune response 56 in adipose tissue, resulting in the production of B cells, T cells, and natural killer (NK) cells that 57 58 can produce a cytokine storm. A cytokine storm is the result of the activity of several immune cells including dendritic cells, macrophages, natural killer cells and T and B lymphocytes. Upon viral 59 infection, the innate immune cells recognize the molecular structure of the invading virus, called 60 61 pathogen associated molecular patterns (PAMPs), by pattern recognition receptors (PRRs) around the cells. The interaction between PRRs and PAMPs triggers signaling pathways that induce the 62 expression of genes encoding proinflammatory cytokines (5). The sudden increase in cytokines, 63 "the cytokine storm", results in accumulation of immune cells into the infection site, causing tissue 64 damage. This can include damage to endothelial cells, the vascular barrier, and its capillaries, as 65 well as diffuse alveolar damage, which may lead to multiorgan failure, and death (6). 66

The immune response cascade is also affected by other key players such as: leptin; Janus kinase 2 (JAK2); and lymphocytes (7). As well as regulating appetite and reproductive functions, leptin is a proinflammatory adipokine secreted by adipose tissue. Thus, leptin contributes to inflammation and may lead to chronic inflammation (7). It directly stimulates macrophages (M1 phenotype), natural killer (NK) cells, dendritic cells (DC) and T-helper cells to secrete proinflammatory cytokines such as IL1, IL6, and TNFα (8).

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is the most important signaling pathway of the leptin receptor. Upon leptin binding, JAK2 activation occurs, which leads to STAT3 binding to phosphorylated tyrosine in leptin receptor followed by expression of responsive genes (9). JAK2 might be imbalanced in patients with obesity could lead to an exaggerated immune response (9).

Lymphocytes, mainly CD4+ T cells and CD8+ T-cells ; play an essential role as antiviral immunity
(10). Patients who had recovered from COVID-19 had high to normal levels of T-cells (11). In
severe cases of SARS-CoV2, patients have low levels of lymphocytes, mainly CD8+ (10).
Therefore, lymphocyte counts have been suggested as possible biomarkers to evaluate the severity
of COVID-19 in patients (11).

The link between obesity and COVID-19 severity has been hypothesized as being, at least partly, due to the immune responses of visceral fat in patients with obesity (6). There have been several reports describing the effects of inflammatory cytokines on COVID-19 infection (12) and the role of obesity in increasing the severity of COVID-19 (10,11).

To test the mediating role of cytokines and related immunological markers in the relationship between BMI and COVD-19 severity, we need to first understand the causal relevance and direction of effects between the different factors. Mendelian randomization (MR) allows us to use

90 genetic variants associated with an exposure of interest as instrumental variables to assess 91 causality. When used as a two-sample approach, summary results from large genome-wide 92 association studies (GWAS) can be used, significantly increasing the number of people we can 93 include in the analysis and, thus, improving our statistical power to detect a modest effect on an 94 outcome (13).

In this study, using publicly-available data from exceptionally large GWAS including hundreds of thousands of individuals and the Mendelian randomization methodology, we aim to investigate the potential mediation role of 41 cytokines, leptin, JAK2, and lymphocyte percentage in the link between obesity and COVID-19 severity. Identifying the mediators of the effect of obesity on COVID-19 severity will allow us to provide epidemiological evidence for targeting specific cytokines that might decrease the risk of COVID-19 on patients with obesity, and which might also have wider consequences for other categories of patients.

102 2 Materials and Methods

103 2.1. Study Design

The study was performed through three MR analyses as outlined in Figure (1): (1) MR analysis was used to estimate the causal association between BMI and severe COVID-19. (2) We also used MR analysis to test the effect of BMI on circulating cytokines and related traits. (3) We conducted MR analysis to identify the circulating cytokines and related traits causally relevant to COVID-19 severity. Finally, we tested whether any of the factors identified as associated with BMI and COVID-19 severity shows evidence of a mediating role between the two, using a multivariable MR and estimating the possible mediating effect.

111 2.2. Selection of genetic instrument variables for BMI

The genetic instruments for BMI were extracted from the Metabochip meta-analysis and genome-wide association study conducted by Locke, *et al.* The study identified 289 BMIassociated loci (at a p-value threshold of $< 5 \times 10^{-8}$) from 322,154 participants of European descent (14).

116 2.3. GWAS summary statistics for COVID-19 severity

COVID-19 severity genetic association data were obtained from the COVID-19 host genetics 117 initiative (COVID-19 HG) GWAS meta-analysis (15) (https://www.COVID-19hg.org/). 118 The 119 COVID-19 HG team has made summary data publicly available on multiple COVID-19 outcomes 120 from several studies. The data acquired for this analysis is with an accession ID: "GCST011073" 121 at the GWAS Catalog of European populations. The study is from May 13, 2020, which is the last 122 time point available before the wide release of the COVID-19 vaccination. Severity of infection is 123 defined as hospitalized COVID-19 Vs. not hospitalized COVID-19 release 5 and includes 38,984 European ancestry cases and 1,644,784 European ancestry controls. The relevant data can be 124 downloaded from (https://www.ebi.ac.uk/gwas/studies/GCST011073) (15). 125

126 2.4. GWAS summary statistics for inflammatory cytokines and C-reactive protein

The summary statistics for inflammatory cytokines were acquired from the work of Kalaoja, *et al.*(12). The authors analyzed a cytokine panel (41 cytokines) from the National FINRISK Study
(1997 and 2002 cohorts) and the Cardiovascular Risk in Young Finns Study (YFS) The full
GWAS summary results for all 41 inflammatory cytokines are available through the University of
Bristol (https://data.bris.ac.uk/data/dataset/3g3i5smgghp0s2uvm1doflkx9x) (16).

132 2.5. GWAS summary statistics for leptin levels, lymphocytes percentage, and Tyrosine-protein
133 kinase JAK2 levels

134	The summary statistics for lymphocyte percentage of leukocytes were obtained from the study by
135	Jung H, et. al. (17) based on data of 174,488 individuals from the UK biobank with European
136	ancestry (U.K.). Lymphocyte percentage was measured by dividing the number of lymphocytes in
137	blood by the total number of white blood cells.
138	Summary statistics data for leptin levels were acquired from the published study by Vaghootkar H
100	Summary statistics data for reprin revers were acquired from the published study by Tughobikar 11.
139	et al. (18) accession ID: "GCST90007310" and downloaded from the GWAS Catalog
140	https://www.ebi.ac.uk/gwas/studies/GCST90007310. Yaghootkar analyzed circulating leptin
141	levels in 49,909 European ancestry individuals for association with exonic genetic variants (18).
142	GWAS of tyrosine-protein kinase (JAK2) levels was obtained from a genome-wide association
143	study of serum proteins published by Gudjonsson. et.al (19), accession ID: "GCST90086866" and
144	was downloaded from the GWAS Catalog https://www.ebi.ac.uk/gwas/studies/GCST90086866.
145	The authors performed a GWAS for 5,355 European Icelandic ancestry individuals with 2,091
146	serum proteins including JAK2 measured through the SOMAmer platform (19).

147

2.6. Statistical Analysis 148

149 All analyses were performed using R (20). The TwoSampleMR package (21) was used for MR 150 and the ggplot2 package (22) for plots, unless otherwise stated. The inverse variance weighted (IVW) approach was considered as the main MR analysis for estimating the causal relationships 151 unless there was evidence for directional pleiotropy. Directional pleiotropy was tested through the 152 intercept term of the MR Egger analysis method (23). In the presence of pleiotropy, we used the 153 weighted median estimate. All p-values with P <0.05 were considered statistically significant. All 154 association estimates were reported as either odd ratios (OR) with 95% confidence intervals (CIs) 155

156 for binary outcomes, or as beta coefficients and 95% CIs for continuous outcome variables. The mediation analysis was performed as described in the supplementary material of Burgess et al (24). 157 Causal Mediation analysis is a method that assesses a hypothetical causal effect of exposure and 158 outcome via a mediator. It separates the total effect into direct and indirect effect whereby the 159 indirect effect includes the hypothetical mediator to the outcome. The total effect is obtained from 160 161 the two main sample MR results. The direct effect of BMI on COVID-19 severity was estimated using a Multivariable Mendelian randomization using the MVMR package in R. Multivariable MR 162 analysis allows the simultaneous estimation of causal effects of multiple exposures on an outcome 163 (25). The indirect effect can then be estimated as the difference between the total and direct effects 164 (Figure 4). 165

166 **3 Results**

167 3.1 The causal effect of BMI on COVID-19 severity

From the previously reported 289 BMI associated SNPs, 187 remained after removing variants with linkage disequilibrium of $r^2 > 0.001$ with any other SNP. All 187 were found in the COVID-19 severity data and were successfully harmonized between the two sets of results. The inverse variance weighted (IVW) estimates showed that BMI was positively associated with COVID-19 hospitalization (OR=1.242; 95% CI 1.034 -1.317, p=1.63 x10⁻⁸). MR Egger was used to test the existence of pleiotropy, and no evidence of directional pleiotropy was present (Intercept 0.0005, *p*value = 0.638).

175

176 3.2 The effect of BMI on inflammatory cytokines

We estimated the effect of BMI on 41 inflammatory cytokines. Genetically-predicted BMI waspositively associated with five inflammatory cytokines with P-value less than 0.05 as shown in

Supplementary Table 1 and Figure 2. The cytokine with the highest magnitude of effect from BMI was hepatocyte growth factor (HGF) ($\beta = 0.277$, se = 0.0703, *p*=8.00 x 10⁻⁵). Other cytokines affected included TNF-related apoptosis-inducing ligand (TRAIL) ($\beta = 0.221$, se = 0.0678, *p*=1.09 x10⁻³), IL 13 ($\beta = 0.226$, se = 0.0916, *p*=1.38 x10⁻²), IL 6 ($\beta = 0.148$, se = 0.0638, *p*=2.01 x10⁻²) and IL 7 ($\beta = 0.196$, se = 0.0992, *p*=4.83 x10⁻²). None of the cytokines tested showed evidence of decreasing with increasing BMI as shown in Figure 2 and Supplementary Table 1, though CTACK was close (b = -0.184, se = 0.097, p = 5.6x10⁻²).

186

187 3.3 The effect of inflammatory cytokines on COVID-19 severity

We tested all 41 inflammatory cytokines for a causal association with COVID-19 severity. Of these, two cytokines were positively associated with severity of COVID-19: TNF α (OR= 1.030 (95% CI 1.011-1.048, *p*=1.72 x 10⁻³) and IL 8 (OR=1.017; 95% CI 1.000 - 1.034, *p*=4.88 x10⁻²). On the other hand, HGF (OR=0.892; 95% CI 0.800-0.984, *p*=1.46 x10⁻²) was the only cytokine with evidence of being inversely associated with COVID-19 severity as shown in Figure 3 and

193 Supplementary Table 2. We found no evidence of directional pleiotropy for any of the associations

- 194 tested using the intercept of the MR Egger model (Figure 3 and Supplementary Table 2).
- 195 3.4 The effect of BMI on each of leptin, JAK2, and lymphocyte percentage
- 196 We analyzed the effect of BMI variants individually on leptin, JAK2, and lymphocyte percentage.
- 197 Genetically-predicted BMI was only statistically significantly associated with leptin ($\beta = 0.732$, se

198 = 0.0798, $p=4.756 \text{ x}10^{-20}$). JAK2 ($\beta = 0.142$, se = 0.101, p=0.16) and lymphocytes ($\beta = 0.0475$,

199 se = 0.0308, p=0.12) showed no evidence of associations.

200 3.5 The effect of leptin, JAK2, and lymphocyte percentage on COVID-19 severity

Leptin-associated genetic variants were positively associated with COVID-19 severity (OR=1.289; 95% CI: 1.0766-1.501, $p=1.92 \times 10^{-2}$), whilst no statistically significant evidence was found between SNPs for JAK2 (OR= 1.006 (95% CI 0.950 – 1.061 , p=0.83) and lymphocyte percentage (OR= 0.989 (95% CI 0.908-1.069, p=0.78) with COVID-19 severity. 3.6 Mediation Analysis

Since no single cytokine measure was associated with both BMI and COVID-19 severity. We measured the indirect causal effect of BMI on COVID-19 severity via all inflammatory cytokines together. Leptin was associated with both BMI and COVID-19 severity, and we also tested its mediation effect (*Figure 4*).

210

211 3.6.1 MVMR of BMI and all inflammatory cytokines on COVID-19 severity

To examine the possible mediation effect of all inflammatory cytokines together, and due to the 212 213 strong correlation between cytokines, we followed a stepwise approach in building our MVMR model by adding inflammatory cytokines, guided by the knowledge of immune response pathways 214 215 to identify those contributing independent information and exclude those causing collinearity. Four 216 non-correlated cytokines were included in the final model, BNGF, GROA, IL2RA, and MIP1A(Supplementary Table 3). The direct effect of BMI (103 SNPs) on COVID-19 severity was 217 218 no longer statistically significant (OR= 0.969 (95% CI 0.812 – 1.125) (Supplementary Table 3, but none of the inflammatory cytokines was statistically significant with COVID-19 severity 219 (Supplementary Table 3). 220

3.6.2 MVMR of BMI and leptin levels on COVID-19 severity.

222	When leptin was included as a conditional factor in the BMI to COVID-19 severity MR model
223	through MVMR, the direct effect of BMI (26 SNPs) on COVID-19 severity was no longer
224	statistically significant (OR= 0.9839 (95% CI 0.752 – 1.216).

225

226 3.7 Causal Mediation Analysis

227 The mediation of the joint inflammatory cytokines was tested. The BMI effect mediated by the cytokines included in the model was estimated as 0.102 (CI -0.0542, 0.2585), but the confidence 228 229 intervals include 0, indicating lack of statistical significance for the estimate (Supplementary 230 Table 4). This represents 52.8% of the total BMI effect estimated, but despite its large value we 231 were not able to find statistical evidence of a mediation effect. Mediation analysis was performed 232 for leptin as it showed evidence of positive association with both BMI and COVID-19. We reestimated the total effect using the BMI SNPs from the MVMR and leptin causal mediation 233 analysis also showed no evidence of a significant association, indirect effect of 0.129 (CI -234 0.1592, 0.4172). Again, although this was 19.7% of the BMI effect on COVID-19 severity, we 235 236 lack the statistical evidence to confirm its presence (Supplementary Table 3).

237

238 4 Discussion

Several studies have identified obesity, particularly as measured by high body mass index (BMI),
as a risk factor for COVID-19 severity. Since obesity also promotes inflammation, the contribution
of cytokines in increasing the risk of severe COVID-19 has been hypothesized, but is not yet well
understood.

Severe forms of COVID-19 are also associated with an overreaction of the immune system through 243 244 a cytokine storm. Here, using a two sample Mendelian randomization approach we confirmed the causal link between obesity, as measured by high BMI, with COVID-19 severity in the form of 245 hospitalization following an infection. We also established the causal effects of genetically-246 predicted BMI on cytokines and of cytokines to COVID-19 severity. We investigated the effect of 247 248 BMI on leptin, JAK2 and lymphocyte percentage and their effect on COVID-19 severity. Mediation analysis was performed for the examined risk factors on the link between BMI and 249 250 COVID-19 severity and although a large proportion of the link between the two can potentially be 251 explained by a combination of cytokines and leptin, we were not able to find clear statistical evidence to support their mediating role. 252

253 Our results agree with both observational and MR studies done previously between BMI and COVID-19 severity: persons with obesity are at higher risk of severe course pf COVID infection. 254 255 The effect we estimated (OR = 1.207; 95% CI: 1.115–1.307;) is close to that reported by several 256 Mendelian randomization studies of BMI and COVID-19 severity. COVID-19 severity in high BMI patients was also observed in a previously published meta-analysis of 167 studies including 257 3 million COVID-19 patients. The meta-analysis was performed to compare the association 258 259 between high BMI hospitalized patients and normal BMI COVID-19 hospitalized patients and the outcome results showed that severity of COVID-19 is 1.5 times higher in obese patients compared 260 261 to non-obese patients. The slight overestimation of the effect of BMI indicates the possible 262 presence of confounding factors between the two. Further support for the causal relationship of 263 obesity to COVID-19 severity was seen in studies showing a decrease in COVID-19 severity in 264 patients following bariatric surgery (26).

We assessed 41 inflammatory cytokines to investigate possible mediators that may drive a more 265 severe reaction to the SARs-COV-2 in individuals with obesity. We found five inflammatory 266 cytokines affected by elevated BMI levels (HGF, TRAIL, IL 13, IL 6, and IL 7). Supporting our 267 finding, the link between obesity and changes in the cytokine profile has also been previously 268 reported (27). Further, Dam et. al. reviewed an increase of proinflammatory cytokines; IL 1, IL 6, 269 270 and TNF α by inducing immune cell infiltration from adipose tissue in cell culture settings using 271 human primary adjpocytes and found adjpose cells are capable of promoting an inflammatory state 272 (28). A two sample Mendelian randomization performed by Kalaoja et. al. identified HGF, MCP-273 1, and TRAIL as significantly associated with BMI variation (12). The increase of the affected cytokines seen in our study is probably due to larger number of independently significant BMI 274 275 variants used compared to other studies.

We carried out two sample Mendelian randomization of inflammatory cytokines with COVID-19 severity and our results indicated causal associations with TNF α and IL 8. Both inflammatory cytokines were investigated in several studies reporting the production of high levels of several inflammatory cytokines as part of initiation of cytokine storm in COVID-19 infection such as IL 2, IL 6, IL 7, IL 8, IL 10, GSCF, IP10, MCP 1, MIP1 A, and TNF α (29–31).

We also carried out mediation analysis to investigate the role of inflammatory cytokines on the link between BMI and COVID-19 severity. We found no statistical evidence of mediation by inflammatory cytokines despite the potentially very large estimated proportion of the mediated effect. Although several studies suggested a role for inflammatory cytokines in promoting COVID-19 severity (32), and explained the role of inflammatory cytokines in obesity (27,33,34), or even explored the network effect of adipokines and cytokines in SARS-CoV-2 (35), to our knowledge,

there is no published evidence of a mediating role of inflammatory cytokines on the relationshipbetween BMI and COVID-19 severity.

Other researchers have investigated the role of leptin on obesity (36,37) and leptin in COVID-19 patients (38,39). Our study confirmed the statistically significant effect of high BMI levels on leptin and added to the evidence linking it to worsening COVID-19. Despite its known proinflammatory effects, we were again unable to find any statistical evidence of a mediating role of leptin in the relationship between BMI and COVID-19 severity and to our knowledge no published study has reported this effect.

We also tested JAK-2 and lymphocyte percentage, both as causal consequence of BMI and as causes of COVID-19 severity. We found no evidence for either. Sun, *et.al.* studied the causal role of different white blood cells including lymphocytes percentage and found no significant role of lymphocytes in COVID-19 severity (40). To our knowledge, no MR study has examined the role of JAK-2 with COVID-19 severity. However, JAK-2 was observed to mediate the signaling pathway of inflammatory cytokines (i.e.: IL 6)(41) and anti-JAK-2 inhibitors are suggested for use to mitigate SARs-CoV-2 infection (42,43).

MR, since it uses genetic variants that commonly explain only a small part of the variation of the 302 303 exposure of interest, frequently require very large sample sizes to identify the modest associations present (44) which has likely affected our ability to obtain statistical evidence for mediation despite 304 305 the high proportion of the effect explained. As GWAS efforts increase in size and more genetic 306 variants are identified, we may be able to confirm this effect in the future. This will require GWAS 307 for cytokines with comparable size to the ones available for BMI and COVID-19, though the 308 difficulty and cost in obtaining these measures may make this challenging. Our work contains 309 additional limitations. A major issue for all MR studies is pleiotropy. To ensure the validity of our

310 results, we used the MR-Egger method to test for the presence of directional pleiotropy. The results indicated that our findings are unaffected by it, but pleiotropy remains a concern in all MR studies, 311 more so when positive effects are reported. In two-sample MR approaches, it is important to use 312 information from comparable populations as systematic changes between them may influence the 313 results (45). Here, our analysis is necessarily restricted to people of European ancestry, due to 314 315 relevant GWAS data availability. It is unclear whether our conclusions hold for other ancestries, 316 as some studies reported differences in the genetic architecture of the traits considered in this work 317 among different ancestries, particularly in inflammatory cytokines secretion and function. 318 Studying healthy individuals in GWAS might also not reflect the cytokine storm initiated in viral infection. GWAS, though powerful, has limitations for studying cytokine response to viruses as it 319 320 captures genetic tendency, a snapshot, rather than the dynamic response during an infection. Finally, the participants of the population study were studied in general without specification to 321 322 sex. Studies showed that inflammatory cytokines and COVID-19 severity are affected by hormonal 323 status especially in females during menopause (46) and pregnancy (47).

324 In our study we used two-sample Mendelian randomization to study the mediating role of inflammatory cytokines and related traits in the link between COVID-19 severity and BMI. We 325 326 investigated the implications of obesity for inflammatory cytokine levels and related traits, and 327 their effect on COVID-19 severity. We found no secure evidence of proinflammatory cytokines, 328 or related traits, mediating the relationship between BMI and increased risk of severe COVID-19 329 in European populations, despite estimating a potentially large mediating effect. Given the 330 increasing levels of obesity worldwide and the establishment of COVID-19 as an endemic 331 infection, the effectiveness of targeting cytokines to break the link between obesity and COVID-332 19 severity, remains an open question. Well-powered randomized control trials will be required to

333	confirm any suitable cytokine related interventions to control the impact of obesity on COVID-19
334	as done previously with the WHO Solidarity study (48). Our results in this respect remain
335	inconclusive. Further work towards better understanding the genetics of the cytokine response,
336	especially during early stages of infections, and the genetic mechanisms of cytokine storm
337	initiation will help us identify potential targets for intervention not only for response to COVID-
338	19 but also for other similar infections and potentially future pandemic-inducing infections.
339	Abbreviations
340	BMI: Body mass index
341	2SMR: Two-sample Mendelian randomization
342	MVMR: Multivariable Mendelian randomization
343	JAK2: Janus Kinase 2
344	IVW: inverse variance weighted approach
345	
346	Declarations
347	Ethics approval and consent to participate
348	The work described has used published summary level data and no ethics approval is required or
349	consent for publication.
350	Consent for publication
351	Not applicable.

352 Availability of data and materials

353 The data used is openly available.

354 Competing interests

- 355 The authors have no competing interests relevant to this work to declare
- 356 Funding
- 357 This work is not associated with any funding.

358 Clinical trial number

359 Not applicable

360 Authors' contributions

- 361 Z.K. performed the research, data acquisition, data interpretation/analysis, manuscript drafting,
- writing, and editing along with designing figures and creating and organizing tables. F.D. Research
- 363 Concept and design and supervision, A.B. Conceptualization. F.D., A.B., E.K., A.A, and S.S.
- 364 review and editing. All authors have read and approved the final manuscript.

365 Corresponding authors

366 Correspondence to Fotios Drenos

367 Acknowledgments

368 Not applicable

369 7 References

- 1. de Leeuw AJM, Oude Luttikhuis MAM, Wellen AC, Müller C, Calkhoven CF. Obesity and its
- 371 impact on COVID-19. J Mol Med Berl Ger. 2021 Apr 6;
- 2. Zhang X, Lewis AM, Moley JR, Brestoff JR. A systematic review and meta-analysis of obesity and
- 373 COVID-19 outcomes. Sci Rep. 2021 Mar 30;11:7193.
- 374 3. Nguyen MTA, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A Subpopulation of
- 375 Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via
- 376 Toll-like Receptors 2 and 4 and JNK-dependent Pathways. J Biol Chem. 2007 Nov
- 377 30;282(48):35279–92.
- 4. Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, et al. COVID-19, cytokines

and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp

380 Rheumatol. 2020;38(2):337–42.

- 381 5. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol.
 382 2020;20(5):269–70.
- Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What
 We Know So Far. Front Immunol. 2020;11:1446.
- 385 7. Naylor C, Petri WA. Leptin Regulation of Immune Responses. Trends Mol Med. 2016
 386 Feb;22(2):88–98.
- 8. Maurya R, Sebastian P, Namdeo M, Devender M, Gertler A. COVID-19 Severity in Obesity: Leptin
- 388 and Inflammatory Cytokine Interplay in the Link Between High Morbidity and Mortality. Front

389 Immunol [Internet]. 2021 Jun 18 [cited 2024 Mar 14];12. Available from:

- 390 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.649359/full
- 391 9. Tu R, Liu X, Dong X, Li R, Liao W, Hou J, et al. Janus kinase 2 (JAK2) methylation and obesity: A
- 392 Mendelian randomization study. Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3484–91.
- 10. Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients
- 394 with COVID-19. Am J Emerg Med. 2021 Aug 1;46:16–9.
- 11. Rezaei M, Marjani M, Tabarsi P, Moniri A, Pourabdollah M, Abtahian Z, et al. Evaluation of
- Lymphocyte Subtypes in COVID-19 Patients. Tanaffos. 2022 Mar;21(3):293–301.
- 12. Kalaoja M, Corbin LJ, Tan VY, Ahola-Olli AV, Havulinna AS, Santalahti K, et al. The Role of
- 398 Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease.
- 399 Obesity. 2021;29(2):428–37.
- 400 13. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
- 401 randomization analyses using summarized data. Int J Epidemiol. 2017 Dec 1;46(6):1734–9.
- 402 14. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass
- 403 index yield new insights for obesity biology. Nature. 2015 Feb;518(7538):197–206.
- 404 15. The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative
- 405 to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2
- 406 virus pandemic. Eur J Hum Genet. 2020 Jun;28(6):715–8.
- 407 16. Corbin LJ, Timpson NJ. Cytokines GWAS results. University of Bristol; 2020.

408	17. Jung H, Jung HU, Baek EJ, Kwon SY, Kang JO, Lim JE, et al. Integration of risk factor polygenic risk
409	score with disease polygenic risk score for disease prediction. Commun Biol. 2024 Feb
410	13;7(1):180.
411	18. Yaghootkar H, Zhang Y, Spracklen CN, Karaderi T, Huang LO, Bradfield J, et al. Genetic Studies
412	of Leptin Concentrations Implicate Leptin in the Regulation of Early Adiposity. Diabetes. 2020
413	Dec;69(12):2806–18.
414	19. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, et al.
415	A genome-wide association study of serum proteins reveals shared loci with common
416	diseases. Nat Commun. 2022 Jan 25;13(1):480.
417	20. R Core Team. R: A language and environment for statistical computing. R Foundation for
418	Statistical Computing. 2024 [cited 2024 Jul 20]. R: The R Project for Statistical Computing.

- 419 Available from: https://www.r-project.org/
- 420 21. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform
- 421 supports systematic causal inference across the human phenome. Loos R, editor. eLife. 2018
 422 May 30;7:e34408.
- 423 22. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New York;
- 424 2016. Available from: https://ggplot2.tidyverse.org
- 425 23. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect
- 426 estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.

427	24. Burgess S, Daniel RM, Butterworth AS, Thompson SG. Network Mendelian randomization: using
428	genetic variants as instrumental variables to investigate mediation in causal pathways. Int J
429	Epidemiol. 2015 Apr;44(2):484–95.
430	25. Burgess S, Thompson SG. Multivariable Mendelian Randomization: The Use of Pleiotropic
431	Genetic Variants to Estimate Causal Effects. Am J Epidemiol. 2015 Feb 15;181(4):251–60.
432	26. Hasnain N, Moeed A, Waqar E, Farhan SA, Amreek F. Efficacy of bariatric surgery in COVID-19
433	patients: An updated systematic review and meta-analysis. Surg Pract Sci. 2022
434	Dec;11:100140.
435	27. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005 May
436	1;115(5):911–9.
437	28. Dam V, Sikder T, Santosa S. From neutrophils to macrophages: differences in regional adipose
438	tissue depots. Obes Rev. 2016;17(1):1–17.
439	29. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An
440	inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020
441	Oct;26(10):1636–43.
442	30. Frisoni P, Neri M, D'Errico S, Alfieri L, Bonuccelli D, Cingolani M, et al. Cytokine storm and
443	histopathological findings in 60 cases of COVID-19-related death: from viral load research to
444	immunohistochemical quantification of major players IL-1 β , IL-6, IL-15 and TNF- α . Forensic Sci
445	Med Pathol. 2022;18(1):4–19.
446	31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
447	novel coronavirus in Wuhan, China. Lancet Lond Engl. 2020;395(10223):497–506.

- 448 32. Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology.
- 449 2022;30(3):789–98.
- 450 33. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations
- 451 of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. 2005 Jul 1;69(1):29–35.
- 452 34. Zuydam NV, Wielscher M, McCarthy M, Jarvelin MR. Increased Obesity Is Causal for Increased
- 453 Inflammation—A Mendelian Randomisation Study. Diabetes. 2018 Jul
- 454 1;67(Supplement_1):217-LB.
- 455 35. Nigro E, D'Agnano V, Quarcio G, Mariniello DF, Bianco A, Daniele A, et al. Exploring the Network
- 456 between Adipocytokines and Inflammatory Response in SARS-CoV-2 Infection: A Scoping
- 457 Review. Nutrients. 2023 Aug 30;15(17):3806.
- 458 36. Kim JW, Kim JH, Lee YJ. The Role of Adipokines in Tumor Progression and Its Association with
- 459 Obesity. Biomedicines. 2024 Jan;12(1):97.
- 460 37. Nambi G, Alghadier M, Elnegamy TE, Basuodan RM, Alwhaibi RM, Vellaiyan A, et al. Clinical
- 461 (BMI and MRI) and Biochemical (Adiponectin, Leptin, TNF-α, and IL-6) Effects of High-Intensity
- 462 Aerobic Training with High-Protein Diet in Children with Obesity Following COVID-19 Infection.
- 463 Int J Environ Res Public Health. 2022 Jun 11;19(12):7194.
- 464 38. Boicean LC, Birlutiu RM, Birlutiu V. Correlations between serum leptin levels and classical
- biomarkers in SARS-CoV-2 infection, in critically ill patients. Microb Pathog. 2023
- 466 Sep;182:106238.

467	39. Réus GZ, Recco KCC, Machado KMSH, Silva RH, Arent CO, Amboni G, et al. COVID-19, Anxiety,
468	and Body Mass Index Increase Leptin Levels: a Cross-sectional Multicentric Study. Mol
469	Neurobiol. 2023 Dec 20;
470	40. Sun Y, Zhou J, Ye K. White Blood Cells and Severe COVID-19: A Mendelian Randomization Study.
471	J Pers Med. 2021 Mar 12;11(3):195.
472	41. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for
473	monocytes and macrophages. Nat Rev Immunol. 2020 Jun;20(6):355–62.
474	42. Khaledi M, Sameni F, Yahyazade S, Radandish M, Owlia P, Bagheri N, et al. COVID-19 and the
475	potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Front Med
476	[Internet]. 2022 Aug 30 [cited 2024 Jul 22];9. Available from:
477	https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.961027/full
478	43. Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19. J
479	Immunother Cancer. 2022 Apr 22;10(4):e002838.
480	44. Burgess S. Sample size and power calculations in Mendelian randomization with a single
481	instrumental variable and a binary outcome. Int J Epidemiol. 2014 Jun;43(3):922–9.
482	45. Carress H, Lawson DJ, Elhaik E. Population genetic considerations for using biobanks as
483	international resources in the pandemic era and beyond. BMC Genomics. 2021 May
484	17;22(1):351.
485	46. Gersh F, Lavie CJ, O'Keefe JH. Menopause Status and Coronavirus Disease 2019 (COVID-19).
486	Clin Infect Dis. 2021 Nov 1;73(9):e2825–6.

- 487 47. Ntounis T, Prokopakis I, Koutras A, Fasoulakis Z, Pittokopitou S, Valsamaki A, et al. Pregnancy
- 488 and COVID-19. J Clin Med. 2022 Nov 9;11(22):6645.
- 489 48. Pan H, Peto R, Henao Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, et al. Remdesivir
- 490 and three other drugs for hospitalised patients with COVID-19: final results of the WHO
- 491 Solidarity randomised trial and updated meta-analyses. The Lancet. 2022 May
- 492 21;399(10339):1941–53.



Figure 1 A simplified illustration of total effect, direct, and indirect effect using two sample Mendelian randomization. Direct effect between exposure (BMI variants) and outcome (COVID-19 severity) is C'. Indirect effect between exposure and outcome through mediator (cytokines) is a'+b'. The total effect is Direct effect + Indirect effect.



Figure 2 Causal effect (betas) from the Two Sample Mendelian randomization analysis of body mass index (BMI) (exposure) with inflammatory cytokines (outcome)



Figure 3 Causal effect estimates (odds ratios and 95% confidence intervals) from the Two-Sample Mendelian randomization analysis of inflammatory cytokines (exposure) with COVID-19 severity (outcome).



Figure 4: A simplified illustration of mediation analysis, direct, and indirect effect using two sample mendelian randomization. Direct effect between exposure (BMI variants) and outcome (COVID-19 severity). Indirect effect between exposure and outcome through mediator (cytokines, JAK2, Leptin, and lymphocytes percentage).